Fed. Circ. Won't Rehear Amgen-Sandoz Biosimilar Dispute
The Federal Circuit on Friday refused to rehear a battle between Amgen Inc. and Sandoz Inc. over the Affordable Care Act's biosimilars pathway, leaving intact a landmark decision interpreting key provisions...To view the full article, register now.
Already a subscriber? Click here to view full article